Literature DB >> 11589650

Cognitive correlates of supratentorial atrophy on MRI in multiple sclerosis.

S G Edwards1, C Liu, L D Blumhardt.   

Abstract

OBJECTIVES: We aimed to investigate associations between neuropsychological indices and normalized volumes of supratentorial structures, and the area of the corpus callosum.
MATERIALS AND METHODS: We studied 40 patients with clinically definite MS, using 3D-acquired MRI (MPRAGE, Magnetization Prepared Rapid Acquisition Gradient Echo) and stereology. Subjects underwent a neuropsychological battery interrogating multiple cognitive domains, from which a global Cognitive Index Score (CIS) was derived.
RESULTS: White matter volumes were significantly correlated with CIS (rho= -0.59, P<0.0001) and with many of the individual cognitive tests. CIS was also significantly correlated with the corpus callosal area (rho= -0.49, P<0.002). Grey matter volumes did not significantly correlate with any cognitive test.
CONCLUSIONS: These volume/function relationships presumably reflect the effects of subcortical axonal and myelin loss on the neural networks that subserve cognition. If serial MRI volume estimations can index accumulating cognitive deficits, this simple technique may be useful in therapeutic trials.

Entities:  

Mesh:

Year:  2001        PMID: 11589650     DOI: 10.1034/j.1600-0404.2001.00270.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  Cognitive functions correlate with white matter architecture in a normal pediatric population: a diffusion tensor MRI study.

Authors:  Vincent J Schmithorst; Marko Wilke; Bernard J Dardzinski; Scott K Holland
Journal:  Hum Brain Mapp       Date:  2005-10       Impact factor: 5.038

2.  Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis.

Authors:  Flavia Nelson; Sushmita Datta; Nereyda Garcia; Nigel L Rozario; Francisco Perez; Gary Cutter; Ponnada A Narayana; Jerry S Wolinsky
Journal:  Mult Scler       Date:  2011-05-04       Impact factor: 6.312

3.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

Review 4.  Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management.

Authors:  Bridget Bagert; Patricia Camplair; Dennis Bourdette
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Corpus callosum damage and cognitive dysfunction in benign MS.

Authors:  Sarlota Mesaros; Maria A Rocca; Gianna Riccitelli; Elisabetta Pagani; Marco Rovaris; Domenico Caputo; Angelo Ghezzi; Ruggero Capra; Antonio Bertolotto; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2009-08       Impact factor: 5.038

Review 6.  Brain atrophy and cognitive impairment in multiple sclerosis: a review.

Authors:  Michael Lanz; Horst K Hahn; Helmut Hildebrandt
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

Review 7.  Correlations between MRI and Information Processing Speed in MS: A Meta-Analysis.

Authors:  S M Rao; A L Martin; R Huelin; E Wissinger; Z Khankhel; E Kim; K Fahrbach
Journal:  Mult Scler Int       Date:  2014-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.